Aclaris Therapeutics (Aclaris Therapeutics) Days Payable

: 131.49 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Aclaris Therapeutics's average Accounts Payable for the three months ended in Dec. 2023 was $9.26 Mil. Aclaris Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $6.43 Mil. Hence, Aclaris Therapeutics's Days Payable for the three months ended in Dec. 2023 was 131.49.

The historical rank and industry rank for Aclaris Therapeutics's Days Payable or its related term are showing as below:

ACRS' s Days Payable Range Over the Past 10 Years
Min: 194.09 Med: 590.09 Max: 1612.86
Current: 195.78

During the past 11 years, Aclaris Therapeutics's highest Days Payable was 1612.86. The lowest was 194.09. And the median was 590.09.

ACRS's Days Payable is ranked better than
78.2% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: 70.41 vs ACRS: 195.78

Aclaris Therapeutics's Days Payable declined from Dec. 2022 (542.98) to Dec. 2023 (131.49). It may suggest that Aclaris Therapeutics accelerated paying its suppliers.

Aclaris Therapeutics Days Payable Historical Data

The historical data trend for Aclaris Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

971.77

539.39

590.09

310.31

194.09

Aclaris Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable																542.98	452.61	562.14	117.37	131.49

Competitive Comparison

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics Days Payable Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Days Payable falls into.

Aclaris Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Aclaris Therapeutics's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (10.351	+	8.878)	/	2 )	/	18.081	*	365
=	9.6145					/	18.081	*	365
=	194.09

Aclaris Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (9.648	+	8.878)	/	2 )	/	6.428	*	365 / 4
=	9.263					/	6.428	*	365 / 4
=	131.49

Aclaris Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (Aclaris Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

8AT:Germany

Address

640 Lee Road, Suite 200, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Executives

Joseph Monahan	officer: Chief Scientific Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Kevin Balthaser	officer: Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
James Loerop	officer: Chief Business Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Douglas J. Manion	officer: Pres and COO	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Neal Walker	director, officer: President and CEO	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Andrew N Schiff	director	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Gail Cawkwell	officer: Chief Medical Officer	C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Frank Ruffo	officer: Chief Financial Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
David N. Gordon	officer: Chief Medical Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Kamil Ali-jackson	officer: Chief Legal Officer	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
James B. Tananbaum	10 percent owner	3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Management Iii, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iii, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund Iv, L.p.	10 percent owner	600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management Iv, Llc	10 percent owner	900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939